Circulating Tumor DNA in Surgical Lung Cancer Patients
- Conditions
- Lung Neoplasms
- Registration Number
- NCT03081741
- Lead Sponsor
- Shenzhen Gene Health Bio Tech Co., Ltd.
- Brief Summary
Conduct a prospective study to detect the change of ctDNA of surgical lung cancer patients.
- Detailed Description
Studies have shown the feasibility of detecting mutation status by blood circulating tumor DNA (ctDNA) in lung cancer patients.
The investigators plan to test the blood ctDNA in surveillance of surgical lung cancer patients. And evaluate the correlation between ctDNA level with tumor relapse or metastasis.
Recruitment & Eligibility
- Status
- UNKNOWN
- Sex
- All
- Target Recruitment
- 500
Aged 18 to 80 years Undergo radical surgery Histologically confirmed diagnosis of lung cancer Considered primary lung cancer by clinical criteria Patients must have given written informed consent
Unable to comply with the study procedure Malignant tumor history Patients who received any treatment prior to resection Unqualified blood samples
Study & Design
- Study Type
- OBSERVATIONAL
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Effect of surgery on ctDNA of lung cancer patients before surgery and 7days after surgery Changes of blood ctDNA of lung cancer patients before and after surgery.
- Secondary Outcome Measures
Name Time Method
Trial Locations
- Locations (1)
Shenzhen Second People's Hospital
🇨🇳Shenzhen, Guangdong, China